This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fisher, M. Articles by Davalos, A. Search for Related Content PubMed PubMed Citation Articles by Fisher, M. Articles by Davalos, A.

(Stroke. 2004;35:367.)
© 2004 American Heart Association, Inc.

Advances in Stroke 2003

Emerging Therapies for Cerebrovascular Disorders

Marc Fisher, MD Antonio Davalos, MD, PhD

From the Departments of Neurology (M.F.), University of Massachusetts Medical School, Worcester, Mass; and Hospital Universitari Doctor Josep Trueta (A.D.), Girona, Spain.

Correspondence to Dr Marc Fisher, UMASS/Memorial Healthcare, 119 Belmont St. Worcester, MA 01605. E-mail fisherm@ummhc.org

Key Words: Advances in Stroke • aneurysm • cerebrovascular disorders • prevention • therapy

An extract of the first 250 words of the full text is provided, because this article has no abstract.

New information about therapeutic interventions regarding several important aspects of cerebrovascular disease has appeared recently. This short review will focus on new therapeutic developments concerning the prevention of ischemic stroke, acute ischemic stroke therapy trials, and, lastly, the management of patients with intracranial aneurysms.

Great strides have been made in the pharmacological management of patients to reduce the risk for developing ischemic stroke. Stroke prevention is now clearly a multimodal endeavor that encompasses not only the use of antithrombotic agents but also the identification and treatment of multiple, potential stroke risk factors.¹ While the precise relationship of elevated total and LDL cholesterol to stroke risk remains to be determined, prior studies clearly demonstrated substantial primary stroke risk reduction with the use of various statins in patients with cardiovascular disease.² A recent report by the Heart Protection Study Collaborative Group (HPS) suggests that the benefits of at least 1 statin, simvastatin, extend to stroke patients as well.³ In this study, 20 536 patients with 1 form of vascular disease or diabetes mellitus were randomized to 40 mg of simvastatin daily or placebo in addition to their baseline medications and followed on average for 5 years. Of patients randomized, 1820 had stroke alone and 1460 had stroke and coronary artery disease. Allocation to simvastatin was associated with an overall 25% reduction in first stroke. Patients with stroke in the study had a similar benefit for subsequent major vascular events, although precise characterization of risk reduction for secondary stroke was not provided. The . . . [Full Text of this Article]

This article has been cited by other articles:

				M. Fisher and for the Stroke Therapy Academic Industry Roundtabl Enhancing the Development and Approval of Acute Stroke Therapies: Stroke Therapy Academic Industry Roundtable Stroke, August 1, 2005; 36(8): 1808 - 1813. [Abstract] [Full Text] [PDF]